Article

Ruboxistaurin slows central DME, does not halt progression

Inhibition of PKC shown to affect changes in retinal blood flow as well as leukocyte adhesion

Related Videos
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
Bausch + Lomb launches its enVista Aspire monofocal and toric IOLs in the European Union
January 14th 2025

Bausch + Lomb launches its enVista Aspire monofocal and toric IOLs in the European Union

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME
January 13th 2025

4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)
January 13th 2025

Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)

Bausch + Lomb acquires Whitecap Biosciences
January 13th 2025

Bausch + Lomb acquires Whitecap Biosciences

© 2025 MJH Life Sciences

All rights reserved.